Table 1.

Cannabis-inspired or -based medicines available today and their pharmaceutical status. FDA, Food and Drug Administration; THC, Δ9-tetrahydrocannabinol; CBD, cannabidiol; CBN, cannabinol; CYP, Cytochrome P450; EU, European Union; UGT, uridine 5′ diphospho-glucuronosyltransferase.

Drug Name	Indication	Basic Formulation	Clinical Studies	Proved Efficacy	Key Limiting Toxicity	Recommended Dosage	Drug–Drug Interactions Reported	Approval	Reference
Drugs of one molecule
MARINOL® (GW Pharmaceuticals, Cambridge, UK)	Appetite stimulation; antiemetic associated with cancer chemotherapy	Dronabinol (synthetic THC)	Yes	Yes	100 mg/day or 30 mg/kg	Appetite stimulation: 2.5 mg twice daily; antiemetic: 5 mg 3–4 times daily		FDA	[16]
EPIDIOLEX® (GW Pharmaceuticals)	Lennox–Gastaut syndrome and Dravet syndrome in patients	Plant derived CBD	Yes	Yes	20 mg/kg/day	5–20 mg/kg/day	CYP1A2, CYP2B6 substrates, uridine 5’ diphospho-glucuronosyltransferase 1A9 (UGT1A9) and UGT2B7. CYP2C8 and CYP2C9 substrates	FDA	[17]
SYNDROS® (Benuvia Therapeutics Inc, Chandler, AZ, USA)	Anorexia; nausea and vomiting associated with cancer chemotherapy	Dronabinol (synthetic THC)	Yes	Yes	25 mg/day	4.2 mg/day	Neuropsychiatric adverse reactions; hemodynamic instability	FDA	[18]
CESAMET® (Valeant Pharma Int, Laval, QC, Canada)	Nausea and vomiting induced by cancer chemotherapy	Nabilone (synthetic THC)	Yes			2 mg/day	Diazepam 5 mg; sodium secobarbital 100 mg; alcohol (absolute) 45 mL; codeine 65 mg	FDA	[19]
INM-755 cream (Inmed pharma, Vancouver, BC, Canada)	Skin diseases and wounds; epidermolysis bullosa	Bacteria Escherichia coli fermentation derived from one rare CBN (Cannabinol)	Yes Phase 1–2 ongoing	No		Two doses of INM-755 cream are currently being tested			[20]
Drugs of combinatoric formulations
SATIVEX® Oromucosal spray (GW Pharmaceuticals)	Pain relief	Plant-derived CBD:THC and terpenes	Yes	Yes	90 mg/day	5–60 mg/day	Reversible inhibitor of CYP3A4, 1A2, 2B6, 2C9, and 2C19	EU, Canada	[21]